Acadia Pharmaceuticals Inc (NASDAQ: ACAD) kicked off on Thursday, up 1.10% from the previous trading day, before settling in for the closing price of $14.57. Over the past 52 weeks, ACAD has traded in a range of $13.40-$20.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 23.80% over the past five years. While this was happening, its average annual earnings per share was recorded -59.88%. With a float of $165.49 million, this company’s outstanding shares have now reached $166.71 million.
Let’s look at the performance matrix of the company that is accounted for 654 employees. In terms of profitability, gross margin is 91.46%, operating margin of 24.1%, and the pretax margin is 26.94%.
Acadia Pharmaceuticals Inc (ACAD) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Acadia Pharmaceuticals Inc is 0.78%, while institutional ownership is 99.17%. The most recent insider transaction that took place on Apr 08 ’25, was worth 40,133. In this transaction EVP, CHIEF FINANCIAL OFFICER of this company sold 2,708 shares at a rate of $14.82, taking the stock ownership to the 59,456 shares. Before that another transaction happened on Apr 08 ’25, when Company’s PRINCIPAL ACCOUNTING OFFICER sold 1,028 for $14.82, making the entire transaction worth $15,235. This insider now owns 22,257 shares in total.
Acadia Pharmaceuticals Inc (ACAD) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -59.88% per share during the next fiscal year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Take a look at Acadia Pharmaceuticals Inc’s (ACAD) current performance indicators. Last quarter, stock had a quick ratio of 2.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.57. Likewise, its price to free cash flow for the trailing twelve months is 15.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.36, a number that is poised to hit -0.00 in the next quarter and is forecasted to reach 0.95 in one year’s time.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) saw its 5-day average volume 1.31 million, a negative change from its year-to-date volume of 2.28 million. As of the previous 9 days, the stock’s Stochastic %D was 51.94%. Additionally, its Average True Range was 0.75.
During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 18.27%, which indicates a significant decrease from 38.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.66% in the past 14 days, which was higher than the 45.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.38, while its 200-day Moving Average is $16.85. Nevertheless, the first resistance level for the watch stands at $14.85 in the near term. At $14.98, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.21. If the price goes on to break the first support level at $14.49, it is likely to go to the next support level at $14.26. Assuming the price breaks the second support level, the third support level stands at $14.14.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats
The company with the Market Capitalisation of 2.46 billion has total of 166,789K Shares Outstanding. Its annual sales at the moment are 957,800 K in contrast with the sum of 226,450 K annual income. Company’s last quarter sales were recorded 259,600 K and last quarter income was 143,740 K.
